11 results about "Epithelial cancer" patented technology

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention belongs to the field of marine natural pharmaceutical chemistry, and particularly provides a marine fungus-derived diterpenes diterpenoid compound as well as a preparation method and application thereof. According to the present invention, the diterpenes diterpenes compound is obtained from the marine fungus Penicillium brasilianum HBU-136, and the chemical structural formula of the marine fungus-derived diterpenes diterpenes compound is represented by the formula I, wherein the chemical structural formula of the marine fungus-derived diterpenes diterpenes compound is represented by the formula I, and the chemical structural formula of the marine fungus-derived diterpenes diterpenes compound is represented by the formula II; experiments prove that the compound has strong inhibitory activity on human gastric cancer cells (MGC-803, AGS and HGC-27), pulmonary epithelial cancer cells (A-549), liver cancer cells (HepG2) and colon cancer cells (SW-620), can be used as an antitumor drug, and has a wide application prospect.

The present invention relates to radiolabeled gemtuzumab ozogamicin antibodies and humanized versions conjugated with the radionuclide astatine 211 The antibody conjugates are used in radiotherapy for the treatment of urothelial cancer, including bladder cancer.

The present invention provides a method of assessing the risk of an individual to suffer from epithelial cancer, an analyzer therefor, and a kit thereof, the method comprising: measuring the content of a metabolite in a sample of the individual, the metabolite comprising urea nitrogen, creatinine, or a combination thereof; and comparing the contents of the metabolites of the negative control group and the sample, when the content of the metabolites of the sample is lower than the content of the metabolites of the negative control group, the individual is assessed to have the risk of suffering from the urinary epithelial cancer, and the kit comprises at least one reagent for identifying the metabolites in the sample of the individual so as to accurately assess the risk.

The invention belongs to the technical field of molecular biomedicine, and particularly relates to a urinary tract epithelial cell marker and application thereof in diagnosis of urinary tract epithelial cell carcinoma. The molecular marker is cytoplasm thyroid hormone binding protein CRYM, and an immunochemical staining experiment proves that the cytoplasm thyroid hormone binding protein CRYM has the potential to serve as a single immunomarker to be used for distinguishing normal urinary tract epithelial cells / reactive hyperplastic urinary tract epithelial cells and urinary tract epithelial cancer cells. Therefore, the kit plays a key identification role in histopathologic diagnosis or urine noninvasive screening of urothelial carcinoma, and provides important technical support for clinical noninvasive diagnosis.

The invention discloses a urinary tract epithelial cancer detection reagent, a detection kit and application thereof. Specifically, the invention provides application of the reagent combination in preparation of the kit, and the reagent combination comprises a reagent for detecting the methylation level or state of a CpG island region comprising the following genes in a sample to be detected: (A) the CpG island region of the DMRTA2 gene is located in a chr1: 50421000-50421550 region; and (B) a CpG island region of any one gene selected from the following groups, or a combination thereof: (B1) the CpG island region of the TWIST1 gene is located in the chr7: 19117550-19118050 region; and (B2) the CpG island region of the VIM gene is located in the chr10: 17229200-17229700 region. The reagent or the kit provided by the invention can realize rapid and high-sensitivity non-invasive detection.

The present invention provides a compound of Formula I, a salt thereof, or a solvate thereof, as described herein, the composition is used for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative diseases, colorectal cancer, medulloblastoma, kidney cancer, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous carcinoma, gastrointestinal stromal tumor, glioma, mucus fibrosarcoma, smooth muscle sarcoma, neuroblastoma, synovial sarcoma, mesothelioma, and the like. Gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer and neurological cancer.

Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, especially locally advanced or metastatic urothelial cancer. Compared to treatment with either of the two drugs alone, treatment with both in combination has a marked synergistic effect and significant therapeutic effect. In addition, the combination treatment had good efficacy for patients with low HER2 IHC expression (1+).

The present disclosure relates to compounds that restore p53 activity and methods of using the compounds in the treatment of various conditions associated with loss of p53 activity, such as cancer, e.g., cancer. Such as sarcoma, epithelial cancer, head and neck cancer, hematological cancer, solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disease, myelodysplastic syndrome, myeloproliferative tumor, and the like; , non-small cell lung cancer, small cell lung cancer, kidney cancer, lung cancer, colon cancer, cervical cancer, and plasma cell tumor (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods of isolating normal stem cells in culture derived from embryonic epithelial tissue and cancer stem cells derived from epithelial cancers and culture medium systems useful for epigenetically stable growth SOLUTION: A method for isolating stem cells from epithelial tissue, preferably columnar epithelial tissue, comprising: (I) culturing dissociated epithelial cells from a columnar epithelial tissue sample to form a stem cell colony; (ii) isolating single stem cells from the cell colony; and (iii) individually culturing the isolated single stem cells from step (ii) to form a culture of purified stem cell clones, wherein: Wherein each of the stem cell clones represents a clonal expansion of epithelial stem cells present in the columnar epithelial tissue sample, thereby isolating epithelial stem cells.SELECTED DRAWING: None

The present invention relates to a method of predicting the clinical outcome of a subject diagnosed with epithelial cancer, such as oral squamous cell carcinoma, and biomarkers for use in the method.